| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, et al. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. PMID 27421137 DOI: 10.18632/Oncotarget.10559 |
0.01 |
|
| 2016 |
Grothey A, Ellis LM. Therapy: Colorectal cancer: how to teach an old drug new tricks. Nature Reviews. Gastroenterology & Hepatology. PMID 27251212 DOI: 10.1038/nrgastro.2016.87 |
0.01 |
|
| 2016 |
Bhattacharya R, Ye XC, Wang R, Ling X, McManus M, Fan F, Boulbes D, Ellis LM. Intracrine VEGF Signaling Mediates the Activity of Pro-survival Pathways in Human Colorectal Cancer Cells. Cancer Research. PMID 26988990 DOI: 10.1158/0008-5472.CAN-15-1605 |
0.01 |
|
| 2016 |
Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet (London, England). PMID 26853587 DOI: 10.1016/S0140-6736(15)01088-0 |
0.01 |
|
| 2016 |
Wang R, Ye X, Bhattacharya R, Boulbes DR, Fan F, Xia L, Ellis LM. A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling. Stem Cells Translational Medicine. PMID 26744411 DOI: 10.5966/sctm.2015-0168 |
0.01 |
|
| 2015 |
Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26304898 DOI: 10.1200/Jco.2015.62.4148 |
0.01 |
|
| 2015 |
Camp ER, Ellis LM. CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3578-80. PMID 26275951 DOI: 10.1158/1078-0432.CCR-14-2900 |
0.01 |
|
| 2015 |
Ellis LM, Blanke CD, Roach N. Losing "Losing the Battle With Cancer". Jama Oncology. 1: 13-4. PMID 26182295 DOI: 10.1001/jamaoncol.2014.188 |
0.01 |
|
| 2015 |
Ellis LM. The erosion of research integrity: the need for culture change. The Lancet. Oncology. 16: 752-4. PMID 26149871 DOI: 10.1016/S1470-2045(15)00085-6 |
0.01 |
|
| 2015 |
Ye X, Fan F, Bhattacharya R, Bellister S, Boulbes DR, Wang R, Xia L, Ivan C, Zheng X, Calin GA, Wang J, Lu X, Ellis LM. VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells. Molecular Cancer Research : McR. PMID 26041938 DOI: 10.1158/1541-7786.MCR-15-0061 |
0.01 |
|
| 2015 |
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520: 697-701. PMID 25901683 DOI: 10.1038/Nature14418 |
0.01 |
|
| 2015 |
Fan F, Bellister S, Lu J, Ye X, Boulbes DR, Tozzi F, Sceusi E, Kopetz S, Tian F, Xia L, Zhou Y, Bhattacharya R, Ellis LM. The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. British Journal of Cancer. 112: 539-46. PMID 25535733 DOI: 10.1038/bjc.2014.620 |
0.01 |
|
| 2015 |
Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 899-906. PMID 25516888 DOI: 10.1158/1078-0432.CCR-14-0894 |
0.01 |
|
| 2015 |
de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature Reviews. Clinical Oncology. 12: 197-212. PMID 25421275 DOI: 10.1038/nrclinonc.2014.202 |
0.01 |
|
| 2014 |
Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, et al. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5956-63. PMID 25316815 DOI: 10.1158/1078-0432.Ccr-14-1582 |
0.01 |
|
| 2014 |
Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, ... ... Ellis LM, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Molecular Cancer Therapeutics. 13: 2876-85. PMID 25281617 DOI: 10.1158/1535-7163.Mct-14-0074 |
0.01 |
|
| 2014 |
Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, et al. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4210-7. PMID 25125258 DOI: 10.1158/1078-0432.Ccr-14-0521 |
0.01 |
|
| 2014 |
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1277-80. PMID 24638016 DOI: 10.1200/Jco.2013.53.8009 |
0.01 |
|
| 2014 |
Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monte D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, ... ... Ellis LM, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis Clinical Cancer Research. 20: 837-846. PMID 24323901 DOI: 10.1158/1078-0432.Ccr-13-1854 |
0.01 |
|
| 2014 |
Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, Calin GA, Ellis LM, Lu X. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Molecular Oncology. 8: 83-92. PMID 24145123 DOI: 10.1016/J.Molonc.2013.09.004 |
0.01 |
|
| 2013 |
Yi J, Xiong W, Gong X, Bellister S, Ellis LM, Liu Q. Analysis of LGR4 receptor distribution in human and mouse tissues. Plos One. 8: e78144. PMID 24205130 DOI: 10.1371/journal.pone.0078144 |
0.01 |
|
| 2013 |
Li M, Gao J, Feng R, Wang Y, Chen X, Sun J, Zhang D, Zhu Z, Ellis LM, Lu M, Lee JE, Feng Z, Liu B. Generation of monoclonal antibody MS17-57 targeting secreted alkaline phosphatase ectopically expressed on the surface of gastrointestinal cancer cells. Plos One. 8: e77398. PMID 24143229 DOI: 10.1371/journal.pone.0077398 |
0.01 |
|
| 2013 |
Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, Dupre E, Xia L, Lu J, Fan F, Bellister S, Ellis LM, Weihua Z. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Molecular Cancer Therapeutics. 12: 2782-91. PMID 24132143 DOI: 10.1158/1535-7163.Mct-13-0098 |
0.01 |
|
| 2013 |
Ellis LM. An audience with : Lee M. Ellis. Interviewd by Man Tsuey Tse. Nature Reviews. Drug Discovery. 12: 572-3. PMID 23868111 DOI: 10.1038/nrd4085 |
0.01 |
|
| 2013 |
Wan G, Zhang X, Langley RR, Liu Y, Hu X, Han C, Peng G, Ellis LM, Jones SN, Lu X. DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Reports. 3: 2100-12. PMID 23791529 DOI: 10.1016/J.Celrep.2013.05.038 |
0.01 |
|
| 2013 |
Mobley A, Linder SK, Braeuer R, Ellis LM, Zwelling L. A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. Plos One. 8: e63221. PMID 23691000 DOI: 10.1371/journal.pone.0063221 |
0.01 |
|
| 2013 |
Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2824-7. PMID 23549876 DOI: 10.1158/1078-0432.CCR-12-3409 |
0.01 |
|
| 2013 |
Ellis LM, Chen EC. Negotiating identity development among undocumented immigrant college students: a grounded theory study. Journal of Counseling Psychology. 60: 251-64. PMID 23421773 DOI: 10.1037/a0031350 |
0.01 |
|
| 2013 |
Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, Maru DM, Hawke DH, Rak J, Mani SA, Zweidler-McKay P, ... Ellis LM, et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell. 23: 171-85. PMID 23375636 DOI: 10.1016/J.Ccr.2012.12.021 |
0.01 |
|
| 2013 |
Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, et al. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 131-61. PMID 23213095 DOI: 10.1200/Jco.2012.47.1938 |
0.01 |
|
| 2013 |
Bilen MA, Taggart MW, Fournier K, Ellis LM, Mansfield PF, Eng C, Royal RE, Overman MJ. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncologica (Stockholm, Sweden). 52: 1044-6. PMID 23020527 DOI: 10.3109/0284186X.2012.724772 |
0.01 |
|
| 2013 |
Tzeng CW, Aloia TA, Vauthey JN, Chang GJ, Ellis LM, Feig BW, Curley SA, Skibber JM, Abdalla EK, You YN, Rodriguez-Bigas MA. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Annals of Surgical Oncology. 20: 482-90. PMID 22932858 DOI: 10.1245/s10434-012-2620-z |
0.01 |
|
| 2012 |
Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Medicine. 1: 5-16. PMID 23342249 DOI: 10.1002/Cam4.4 |
0.01 |
|
| 2012 |
Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer. 118: 6188-98. PMID 22673945 DOI: 10.1002/Cncr.27653 |
0.01 |
|
| 2012 |
Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3982-91. PMID 22661538 DOI: 10.1158/1078-0432.Ccr-11-2951 |
0.01 |
|
| 2012 |
Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 33: 1327-31. PMID 22505654 DOI: 10.1093/Carcin/Bgs147 |
0.01 |
|
| 2012 |
Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 483: 531-3. PMID 22460880 DOI: 10.1038/483531a |
0.01 |
|
| 2012 |
Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy--evolving view based on clinical trial results. Nature Reviews. Clinical Oncology. 9: 297-303. PMID 22330688 DOI: 10.1038/nrclinonc.2012.8 |
0.01 |
|
| 2012 |
Lin M, Eng C, Hawk ET, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin J. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis. 33: 841-7. PMID 22318908 DOI: 10.1093/Carcin/Bgs096 |
0.01 |
|
| 2012 |
Sood AK, Coleman RL, Ellis LM. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 345-7. PMID 22184398 DOI: 10.1200/Jco.2011.38.8413 |
0.01 |
|
| 2012 |
Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher H, Widger W, Ellis LM, Weihua Z. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Research. 72: 304-14. PMID 22084398 DOI: 10.1158/0008-5472.Can-11-1674 |
0.01 |
|
| 2011 |
Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, ... ... Ellis LM, et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discovery. 1: 580-6. PMID 22180853 DOI: 10.1158/2159-8290.Cd-11-0215 |
0.01 |
|
| 2011 |
Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. British Journal of Cancer. 105: 1759-67. PMID 22045189 DOI: 10.1038/Bjc.2011.449 |
0.01 |
|
| 2011 |
Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinal cancer cell lines. Plos One. 6: e23208. PMID 22028766 DOI: 10.1371/Journal.Pone.0023208 |
0.01 |
|
| 2011 |
Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, ... ... Ellis LM, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. The Journal of Clinical Investigation. 121: 4526-36. PMID 21985787 DOI: 10.1172/Jci45008 |
0.01 |
|
| 2011 |
Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, ... ... Ellis LM, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 141: 1728-37. PMID 21806944 DOI: 10.1053/J.Gastro.2011.07.037 |
0.01 |
|
| 2011 |
Parikh AA, Ellis LM. Circulating angiogenic factors, tumor cells, and outcome after resection of metastatic colorectal cancer--what does it mean? Annals of Surgical Oncology. 18: 2111-3. PMID 21626082 DOI: 10.1245/s10434-011-1765-5 |
0.01 |
|
| 2011 |
Gonzalez-Angulo AM, Hortobagyi GN, Ellis LM. Targeted therapies: peaking beneath the surface of recent bevacizumab trials. Nature Reviews. Clinical Oncology. 8: 319-20. PMID 21556024 DOI: 10.1038/nrclinonc.2011.66 |
0.01 |
|
| 2011 |
Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, ... ... Ellis LM, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (New York, N.Y.). 13: 309-19. PMID 21472135 DOI: 10.1593/Neo.101372 |
0.01 |
|
| 2011 |
Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L, Bose D, Ramachandran V, Ellis LM. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. British Journal of Cancer. 104: 1270-7. PMID 21407219 DOI: 10.1038/Bjc.2011.81 |
0.01 |
|
| 2011 |
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 934-43. PMID 21263089 DOI: 10.1200/JCO.2010.33.2056 |
0.01 |
|
| 2011 |
Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene. 30: 1205-12. PMID 21057529 DOI: 10.1038/Onc.2010.496 |
0.01 |
|
| 2010 |
Ellis LM, Samuel S, Sceusi E. Varying opinions on the authenticity of a human midgut carcinoid cell line--letter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5365-6. PMID 20959409 DOI: 10.1158/1078-0432.Ccr-10-2550 |
0.01 |
|
| 2010 |
Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nature Medicine. 16: 974-5. PMID 20823880 DOI: 10.1038/Nm0910-974 |
0.01 |
|
| 2010 |
Ellis LM, Reardon DA. Is there really a yin and yang to VEGF-targeted therapies? The Lancet. Oncology. 11: 809-11. PMID 20634133 DOI: 10.1016/S1470-2045(10)70161-3 |
0.01 |
|
| 2010 |
Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. The Lancet. Oncology. 11: 373-82. PMID 20171141 DOI: 10.1016/S1470-2045(09)70341-9 |
0.01 |
|
| 2010 |
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 453-9. PMID 20008624 DOI: 10.1200/JCO.2009.24.8252 |
0.01 |
|
| 2010 |
Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death and Differentiation. 17: 499-512. PMID 19834490 DOI: 10.1038/Cdd.2009.152 |
0.01 |
|
| 2010 |
Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 76: 824-30. PMID 19464823 DOI: 10.1016/j.ijrobp.2009.02.037 |
0.01 |
|
| 2009 |
Ellis LM, Hicklin DJ. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7471-7478. PMID 20008847 DOI: 10.1158/1078-0432.CCR-09-1070 |
0.01 |
|
| 2009 |
Zeitlin BD, Ellis LM, Nör JE. Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/{beta}-catenin Crosstalk Leads to Tumor Cell Death. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7453-7455. PMID 20008844 DOI: 10.1158/1078-0432.Ccr-09-2578 |
0.01 |
|
| 2009 |
Gaur P, Bielenberg DR, Samuel S, Bose D, Zhou Y, Gray MJ, Dallas NA, Fan F, Xia L, Lu J, Ellis LM. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6763-70. PMID 19887479 DOI: 10.1158/1078-0432.Ccr-09-1810 |
0.01 |
|
| 2009 |
Van Buren G, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, Ellis LM. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer. 115: 3360-8. PMID 19484792 DOI: 10.1002/cncr.24371 |
0.01 |
|
| 2009 |
Gaur P, Bose D, Samuel S, Ellis LM. Targeting tumor angiogenesis. Seminars in Oncology. 36: S12-9. PMID 19393831 DOI: 10.1053/J.Seminoncol.2009.02.002 |
0.01 |
|
| 2009 |
Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Research. 69: 3842-9. PMID 19383922 DOI: 10.1158/0008-5472.CAN-08-2246 |
0.01 |
|
| 2009 |
Ellis LM, Reardon DA. Cancer: The nuances of therapy. Nature. 458: 290-2. PMID 19295595 DOI: 10.1038/458290a |
0.01 |
|
| 2009 |
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Research. 69: 1951-7. PMID 19244128 DOI: 10.1158/0008-5472.Can-08-2023 |
0.01 |
|
| 2009 |
Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. International Journal of Cancer. Journal International Du Cancer. 124: 1045-53. PMID 19058181 DOI: 10.1002/Ijc.24028 |
0.01 |
|
| 2008 |
Dallas NA, Gray MJ, Xia L, Fan F, van Buren G, Gaur P, Samuel S, Lim SJ, Arumugam T, Ramachandran V, Wang H, Ellis LM. Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8052-60. PMID 19088020 DOI: 10.1158/1078-0432.Ccr-08-1520 |
0.01 |
|
| 2008 |
Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5344-51. PMID 18936472 DOI: 10.1200/Jco.2008.17.5299 |
0.01 |
|
| 2008 |
Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6371-5. PMID 18927275 DOI: 10.1158/1078-0432.CCR-07-5287 |
0.01 |
|
| 2008 |
Ellis LM, Haller DG. Bevacizumab beyond progression: does this make sense? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5313-5. PMID 18854567 DOI: 10.1200/JCO.2008.17.4540 |
0.01 |
|
| 2008 |
Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5254-60. PMID 18854565 DOI: 10.1200/JCO.2008.17.7857 |
0.01 |
|
| 2008 |
Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 27: 7192-200. PMID 18806828 DOI: 10.1038/Onc.2008.356 |
0.01 |
|
| 2008 |
Fan F, Gray MJ, Dallas NA, Yang AD, Van Buren G, Camp ER, Ellis LM. Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Molecular Cancer Therapeutics. 7: 3064-70. PMID 18790786 DOI: 10.1158/1535-7163.MCT-08-0615 |
0.01 |
|
| 2008 |
Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. International Journal of Cancer. Journal International Du Cancer. 123: 1883-91. PMID 18688864 DOI: 10.1002/Ijc.23730 |
0.01 |
|
| 2008 |
Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews. Cancer. 8: 579-91. PMID 18596824 DOI: 10.1038/nrc2403 |
0.01 |
|
| 2008 |
Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer Journal (Sudbury, Mass.). 14: 170-7. PMID 18536556 DOI: 10.1097/PPO.0b013e318178d9de |
0.01 |
|
| 2008 |
Van Buren G, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, Fan F, Somcio R, Wu Y, Hicklin DJ, Ellis LM. Effect of molecular therapeutics on liver regeneration in a murine model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1836-42. PMID 18398149 DOI: 10.1200/JCO.2007.11.6566 |
0.01 |
|
| 2008 |
Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. American Journal of Obstetrics and Gynecology. 198: 477.e1-9; discussion. PMID 18395047 DOI: 10.1016/J.Ajog.2007.12.028 |
0.01 |
|
| 2008 |
Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1931-7. PMID 18381930 DOI: 10.1158/1078-0432.Ccr-07-4478 |
0.01 |
|
| 2008 |
Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, ... Ellis LM, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. Journal of the National Cancer Institute. 100: 109-20. PMID 18182619 DOI: 10.1093/Jnci/Djm279 |
0.01 |
|
| 2008 |
Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN. Management of bevacizumab-associated bowel perforation: A case series and review of the literature Annals of Oncology. 19: 577-582. PMID 18024857 DOI: 10.1093/annonc/mdm508 |
0.01 |
|
| 2007 |
Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7432-40. PMID 18094427 DOI: 10.1158/1078-0432.CCR-07-1768 |
0.01 |
|
| 2007 |
Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JN. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 110: 2761-7. PMID 17960603 DOI: 10.1002/cncr.23099 |
0.01 |
|
| 2007 |
Stoeltzing O, Liu W, Fan F, Wagner C, Stengel K, Somcio RJ, Reinmuth N, Parikh AA, Hicklin DJ, Ellis LM. Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system Cancer Letters. 258: 291-300. PMID 17950526 DOI: 10.1016/j.canlet.2007.09.009 |
0.01 |
|
| 2007 |
Dallas NA, Fan F, Gray MJ, Van Buren G, Lim SJ, Xia L, Ellis LM. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Reviews. 26: 433-41. PMID 17786539 DOI: 10.1007/s10555-007-9070-2 |
0.01 |
|
| 2007 |
Van Buren G, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, Somcio R, Fan F, Camp ER, Yao JC, Ellis LM. The development and characterization of a human midgut carcinoid cell line. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4704-12. PMID 17699847 DOI: 10.1158/1078-0432.CCR-06-2723 |
0.01 |
|
| 2007 |
Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R, Ellis LM. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Annals of Surgical Oncology. 14: 2838-46. PMID 17653802 DOI: 10.1245/s10434-007-9486-5 |
0.01 |
|
| 2007 |
McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. The Journal of Clinical Investigation. 117: 2114-22. PMID 17641778 DOI: 10.1172/Jci31334 |
0.01 |
|
| 2007 |
Hoff PM, Ellis LM. Targeted therapy trials: approval strategies, target validation, or helping patients? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1639-41. PMID 17470854 DOI: 10.1200/JCO.2006.09.8384 |
0.01 |
|
| 2007 |
Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer. 109: 1030-9. PMID 17311308 DOI: 10.1002/cncr.22490 |
0.01 |
|
| 2007 |
Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model International Journal of Cancer. 120: 1803-1810. PMID 17230506 DOI: 10.1002/ijc.22442 |
0.01 |
|
| 2006 |
Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Seminars in Oncology. 33: S1-7. PMID 17145519 DOI: 10.1053/j.seminoncol.2006.08.002 |
0.01 |
|
| 2006 |
Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clinical & Experimental Metastasis. 23: 301-13. PMID 17086355 DOI: 10.1007/S10585-006-9040-Z |
0.01 |
|
| 2006 |
Van Buren G, Camp ER, Yang AD, Gray MJ, Fan F, Somcio R, Ellis LM. The role of nitric oxide in mediating tumour blood flow. Expert Opinion On Therapeutic Targets. 10: 689-701. PMID 16981826 DOI: 10.1517/14728222.10.5.689 |
0.01 |
|
| 2006 |
Stoeltzing O, Meric-Bernstam F, Ellis LM. Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell. 10: 89-91. PMID 16904605 DOI: 10.1016/j.ccr.2006.07.013 |
0.01 |
|
| 2006 |
Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE, Ellis LM. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Molecular Cancer Therapeutics. 5: 1676-82. PMID 16891453 DOI: 10.1158/1535-7163.MCT-05-0175 |
0.01 |
|
| 2006 |
Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4147-53. PMID 16857785 DOI: 10.1158/1078-0432.CCR-06-0038 |
0.01 |
|
| 2006 |
Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Archives of Surgery (Chicago, Ill. : 1960). 141: 537-43; discussion 5. PMID 16785353 DOI: 10.1001/Archsurg.141.6.537 |
0.01 |
|
| Hide low-probability matches. |